230 related articles for article (PubMed ID: 30334467)
1. An update on treatment of higher risk myelodysplastic syndromes.
Rahmé R; Adès L
Expert Rev Hematol; 2019 Jan; 12(1):61-70. PubMed ID: 30334467
[TBL] [Abstract][Full Text] [Related]
2. [Treating high-risk myelodysplastic syndromes].
Adès L
Bull Cancer; 2023 Nov; 110(11):1162-1167. PubMed ID: 37407322
[TBL] [Abstract][Full Text] [Related]
3. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
6. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
Curr Hematol Malig Rep; 2024 Jun; 19(3):138-150. PubMed ID: 38632155
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in the treatment of myelodysplastic syndromes].
Gelsi-Boyer V; Vey N
Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
[TBL] [Abstract][Full Text] [Related]
10. Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
Madanat YF; Xie Z; Zeidan AM
Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes current treatment algorithm 2018.
Steensma DP
Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
[TBL] [Abstract][Full Text] [Related]
12. How I treat MDS after hypomethylating agent failure.
Santini V
Blood; 2019 Feb; 133(6):521-529. PubMed ID: 30545832
[TBL] [Abstract][Full Text] [Related]
13.
Shallis RM; Podoltsev NA; Gowda L; Zeidan AM; Gore SD
Expert Rev Hematol; 2020 May; 13(5):447-460. PubMed ID: 32182435
[No Abstract] [Full Text] [Related]
14. Emerging biological therapies for the treatment of myelodysplastic syndromes.
Zeidan AM; Stahl M; Komrokji R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
[TBL] [Abstract][Full Text] [Related]
16. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
17. An update on the treatment of myelodysplastic syndromes.
Kurtin SE; Demakos EP
Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
[TBL] [Abstract][Full Text] [Related]
18. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
19. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]